Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Itraconazole

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 4 (1)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT06307223Phase 4CompletedPrimary

Efficacy and Safety of 30% Supramolecular Salicylic Acid Combined With Supramolecular Active Zinc in the Treatment of Malassezia Folliculitis

NCT04886323Not ApplicableCompletedPrimary

Effect of Cold Atmospheric Plasma on Malassezia Folliculitis

Showing all 2 trials

Research Network

Common Treatments

  • Itraconazole1
  • 30 Supramolecular Salicylic Acid1
  • Cold Atmospheric Plasma Treatment Device1
  • Supramolecular Active Zinc1

Active Sponsors

  • Hefei CAS Ion Medical and Technical Devices Co.,Ltd1
  • Second Affiliated Hospital of Xi'an Jiaotong University1
  • The Second Hospital of Anhui Medical University1

Top Investigators

  • Jing Gao1

    The Second Hospital of Anhui Medical University

  • Weihui zeng1

    Second Affiliated Hospital of Xi'an Jiaotong University

  • Jingwen Wang1

    The Second Hospital of Anhui Medical University

  • Chunjun Yang1

    The Second Hospital of Anhui Medical University

  • Liyun Wang1

    The Second Hospital of Anhui Medical University

Activity Timeline